MFAT, micro-fragmented adipose tissue, is a preparation of mechanically processed fat tissue that retains an intact stromal vascular niche, including adipose-derived stem cells, pericytes, and extracellular matrix components, and is injected at the site of injury or disease. Multiple clinical trials have evaluated MFAT injections for orthopedic applications, particularly knee osteoarthritis, with published data demonstrating improvements in pain and functional outcomes. MFAT is not FDA-approved as a treatment for any condition. It is an investigational approach being studied in clinical trials. This post explains what MFAT is, what the current evidence shows, how it differs from banking, and what a patient or physician considering MFAT should know about the regulatory context.
TLDR: MFAT (micro-fragmented adipose tissue) is mechanically processed fat tissue injected at the site of disease or injury. It is not FDA-approved as a treatment. Multiple clinical trials have studied MFAT for knee osteoarthritis and other orthopedic applications, with published data showing improvements in pain and function. MFAT and banking are different services addressing different timelines. MFAT uses tissue on the same day it is harvested. Banking preserves cells in long-term cryostorage for future use.
Important Disclaimer: Save My Fat does not provide MFAT injections or any FDA-approved treatments or cures for any disease. MFAT is an investigational procedure studied in clinical trials and is not an FDA-approved therapy for any condition. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Consult your physician before making any healthcare decision.
If you searched for MFAT injections, you probably already know the basics. It is a procedure involving processed fat tissue injected into a joint or injury site, and it is being offered at some clinics for conditions like knee arthritis. What you may not know is where it sits regulatorily, what the clinical evidence actually shows, how it compares to the banking approach, and what questions to ask before proceeding with any adipose tissue procedure. This post gives you all of that.
For physicians evaluating MFAT as a service offering, the relevant questions are different but related. What does the published evidence actually support? What is the FDA’s current position on MFAT’s regulatory classification? How does MFAT sit alongside banking, as a competitor, a complement, or a different product for a different patient need? The short answer is that MFAT and banking are not competitors. They serve different timelines and different patient decisions, and a practice can offer both.
This post covers the MFAT procedure itself, the clinical trial evidence base, the regulatory landscape, the comparison to banking, and the framework for how a patient or physician should think about both options.
What MFAT Is
The Procedure
MFAT is produced by mechanically processing harvested subcutaneous fat. The processing method, typically using a closed, single-use device, mechanically disrupts the fat tissue into micro-fragments while preserving the extracellular matrix scaffolding and the resident cell populations within it, including adipose-derived stem cells, pericytes, smooth muscle cells, and endothelial cells. The published characterization data on the Lipogems system from Bianchi and colleagues in 2015 established the biological profile of mechanically processed fat, and the subsequent review of the approach by Tremolada and colleagues covers the technique in more depth. Save My Fat’s patient-facing overview of adipose-derived stem cells provides the underlying biological context for both this procedure and banking.
What Is Injected
MFAT is a tissue preparation rather than an isolated cell product. The injection contains micro-fragments of fat tissue with their cellular architecture and extracellular matrix largely intact. The proposed mechanism of action in orthopedic applications is a combination of three effects. Direct differentiation of resident mesenchymal stromal cells into cartilage-supporting cell types is one. Anti-inflammatory paracrine signaling from the resident cell populations is the second. Mechanical cushioning from the extracellular matrix components is the third. The clinical evidence base on MFAT in knee osteoarthritis, supplemented by additional outcomes data, has tested these mechanisms clinically rather than only in the laboratory. Save My Fat’s overview of how mesenchymal stem cells compare across sources covers the biological reasons adipose-derived cell populations have attracted this level of clinical investigation.
Same-Day Procedure
MFAT is typically a same-day procedure. The fat is harvested in the morning, processed immediately using a closed mechanical device without a laboratory, and injected at the target site during the same visit. There is no cryopreservation step. The tissue is used fresh, not stored. This is the defining structural difference from banking, and it determines which service fits which patient decision. MFAT uses tissue today. Banking stores tissue for future use.
What the Evidence Shows
Knee Osteoarthritis
The majority of published MFAT clinical evidence comes from orthopedic applications, with knee osteoarthritis being the most studied indication. Published trials and outcomes data together with systematic reviews have reported improvements in pain scores and functional outcomes at twelve-month follow-up in patients receiving MFAT injections for moderate knee osteoarthritis, and the broader ADSC orthopedic systematic review literature provides context on how MFAT outcomes fit within the larger adipose-derived cell evidence base in joint disease. The Lipogems system, which is the most widely studied MFAT processing device, has been used in multiple registered clinical trials, including NCT02726945 evaluating MFAT for knee osteoarthritis.
Other Orthopedic Applications
Beyond knee osteoarthritis, published studies have evaluated MFAT in hip osteoarthritis, rotator cuff pathology, plantar fasciitis, and tendon injuries. Results across these applications have generally been favorable for pain and function outcomes in early-phase studies, with most evidence coming from single-center observational studies and small randomized trials. Patients or physicians interested in the full active pipeline can search the ongoing micro-fragmented adipose tissue trials on ClinicalTrials.gov to see which specific indications are currently recruiting participants.
What the Evidence Does Not Establish
The published evidence does not establish MFAT as a proven or FDA-approved treatment for any condition. Most published studies are early-phase, single-center, and without long-term follow-up beyond twelve to twenty-four months. Placebo-controlled trial data is limited. The mechanism of action is plausible and supported by in vitro and preclinical data but has not been definitively confirmed in large Phase 3 trials. The broader ADSC knee osteoarthritis meta-analysis literature reflects both the promise and the evidentiary limits of the field. This is honest context that a patient or physician evaluating MFAT deserves to have before making any decision.
The Regulatory Landscape for MFAT
Where MFAT Sits Under FDA Rules
MFAT’s regulatory classification is one of the most frequently misunderstood aspects of this procedure. The key question is whether mechanical processing of fat tissue for same-day injection meets the minimal manipulation standard under FDA Section 361 HCT/P, codified at 21 CFR Part 1271.
The FDA’s position on MFAT and mechanically processed fat products has been nuanced rather than categorical. Mechanical processing alone does not automatically qualify a product as minimally manipulated. The agency evaluates whether the processing alters the relevant biological characteristics of the tissue. Mechanical fragmentation that preserves the tissue architecture is generally treated differently from enzymatic digestion, but providers offering MFAT should consult their own legal and regulatory counsel on the specific regulatory status of the device and processing method they are using. The FDA’s tissue products page is the primary federal reference for how the agency approaches this regulatory analysis. Save My Fat’s overviews of FDA regulations for adipose tissue and 21 CFR Part 1271 cover the framework in physician-appropriate depth, though neither addresses MFAT-specific regulatory questions directly.
What This Means for Patients
A patient being offered MFAT injections should ask four specific questions. Is this procedure being performed under a registered clinical trial or expanded access program? What FDA regulatory framework does the provider say governs this procedure? What is the specific processing device being used and what is its regulatory status? What claims is the provider making about what MFAT will do for my condition?
Any provider making disease treatment claims for MFAT without FDA approval is operating in a regulatory risk zone. The distinction between “this is an investigational procedure studied in clinical trials for joint pain” and “this will treat your arthritis” is significant, and the FDA has issued consumer alerts on regenerative medicine products specifically because of the prevalence of the second kind of claim in clinic marketing. Save My Fat’s guides on fake stem cell clinic red flags and banking vs. stem cell treatment clinics cover the enforcement-target patterns patients should be aware of.
MFAT vs. Banking: Two Different Timelines
MFAT and banking are not competing services. They address different patient decisions on different timelines.
| Feature | MFAT Injection | Adipose Tissue Banking |
|---|---|---|
| When tissue is used | Same day as harvest | Future, months to years later |
| Processing method | Mechanical fragmentation, same-day | Cell isolation and cryopreservation |
| Storage | None, tissue used immediately | Long-term liquid nitrogen cryostorage |
| Regulatory framework | Section 361 HCT/P (device-dependent) | Section 361 HCT/P (minimal manipulation, autologous) |
| FDA approval status | Not approved as a treatment | Not a treatment, a preservation service |
| Clinical evidence | Active trial base, orthopedic-focused | Cells preserved for future FDA-regulated pathways |
| Patient decision | “I want treatment now for a current condition” | “I want to preserve options for future therapies” |
The clinical review of MFAT and the 21 CFR Part 1271 regulatory framework together define the distinction between these two services. Save My Fat’s overview of how banking works describes the banking workflow in more depth.
Can a Patient Do Both?
Yes, with an important sequencing note. A patient who wants MFAT for a current joint condition and also wants to bank for future use should discuss the order of operations with their physician. Banking first preserves the best quality cells at the patient’s current biological age, which matters because cell quality declines with age. MFAT can follow independently. In some cases the harvest for banking and the harvest for MFAT can be coordinated in the same procedure visit, though the logistics depend on the specific provider protocol and the device being used for the MFAT preparation. The complete guide to banking and the active MFAT injection trial pipeline on ClinicalTrials.gov are both worth reviewing before making a decision about sequencing.
For Physicians: Offering Both
A physician already offering or evaluating MFAT is a natural fit for the Save My Fat banking network. The harvest technique is the same or closely related. The patient population overlaps almost entirely. Both services appeal to health-forward adults concerned about joint health and long-term wellbeing. The regulatory and training infrastructure for banking complements an existing MFAT practice rather than duplicating it, and a practice that offers both can serve the patient who wants a current-condition intervention together with the patient who wants to preserve biological optionality for the future. The Save My Fat provider program is structured to accommodate practices already operating in the regenerative medicine space.
Active Clinical Trials in MFAT
For patients or physicians who want to evaluate MFAT through the most rigorous available pathway, a registered clinical trial is that pathway. Current recruiting studies can be found by searching the micro-fragmented adipose tissue trial list and the MFAT injection trial list on ClinicalTrials.gov. Save My Fat’s overview of finding legitimate clinical trials covers how to interpret the registry entries and what to look for in a trial before enrolling.
Participating in a registered trial provides access to MFAT under the most transparent, monitored, and ethically reviewed conditions available. For patients with qualifying conditions, trial enrollment is worth exploring before paying out-of-pocket for a procedure at an unregistered clinic. Save My Fat’s resources on expanded access programs and what ClinicalTrials.gov phases actually mean give patients the research framework for making that evaluation.
Frequently Asked Questions
Is MFAT FDA-approved for knee arthritis?
No. MFAT is not FDA-approved as a treatment for knee arthritis or any other condition. It is an investigational procedure with an active clinical trial evidence base, and the FDA’s tissue products framework is the primary regulatory reference for how mechanically processed adipose products are evaluated. Providers offering MFAT outside of a registered clinical trial are operating in an area that requires careful regulatory consideration, and patients should ask specifically about which framework the provider is operating under.
How is MFAT different from PRP?
Platelet-rich plasma is a blood-derived product containing concentrated growth factors. MFAT is a fat-derived tissue preparation containing stem cells, pericytes, and extracellular matrix. Both are used in orthopedic applications and both are investigational rather than FDA-approved as treatments. The cell populations, the proposed mechanisms, and the published clinical evidence bases for each are distinct, though they are sometimes offered by the same practices for overlapping patient populations.
How is MFAT different from stromal vascular fraction preparations?
Stromal vascular fraction preparations are produced by enzymatic digestion of fat tissue to isolate cells, then reinjecting the isolated cells. MFAT retains the tissue micro-architecture through mechanical processing only. The FDA has applied greater scrutiny to preparations involving enzymatic digestion, because enzymatic processing may not meet the minimal manipulation standard under Section 361 HCT/P. MFAT’s mechanical-only approach is generally treated differently in this regulatory analysis, and the published characterization literature on the Lipogems system documents the biological basis for that distinction.
Can my physician offer MFAT and banking?
Yes. The two procedures use the same source tissue and closely related harvest techniques. A physician partner in the Save My Fat provider network is well-positioned to offer both, and the patient population for both overlaps significantly. Banking requires no additional equipment beyond what an MFAT practice already has, and the Save My Fat onboarding is designed to accommodate practices already operating in the regenerative medicine space.
Should I bank before getting MFAT injections?
Banking and MFAT serve different purposes and different timelines. If you are considering both, the question of sequencing is worth discussing with your physician. Banking preserves cells at your current biological age, and earlier is biologically better because cell function declines over time. MFAT addresses a current condition. They are not mutually exclusive, and Save My Fat’s resource on questions to ask before banking gives patients a framework for the sequencing conversation with their provider.
Key Takeaways
MFAT is mechanically processed fat tissue injected at the site of disease or injury. It is a same-day procedure using freshly processed tissue rather than cryopreserved cells, and the processing preserves the tissue micro-architecture through mechanical fragmentation alone.
Multiple clinical trials have evaluated MFAT for knee osteoarthritis and other orthopedic applications, with published data showing improvements in pain and functional outcomes. The evidence base is promising but comes largely from early-phase and single-center studies. Placebo-controlled data is limited, and long-term follow-up beyond twelve to twenty-four months is rare in the published literature.
MFAT is not FDA-approved as a treatment for any condition. This is the single most important fact for a patient to understand before agreeing to the procedure. A provider representing MFAT as an approved treatment for a specific disease is operating outside the regulatory framework the FDA has established for adipose tissue preparations.
MFAT’s regulatory status depends on whether the specific processing method meets the minimal manipulation standard under FDA Section 361 HCT/P. The analysis is device-specific and fact-specific, not categorical, and providers offering MFAT should consult their own regulatory counsel rather than relying on general industry claims about the procedure’s FDA status.
MFAT and banking are not competitors. They serve different timelines and different patient decisions. MFAT addresses current conditions with same-day tissue. Banking preserves cells for future FDA-regulated pathways. Patients who want both can potentially coordinate the two services, and physicians already offering MFAT are a natural fit for the Save My Fat banking network.
Patients considering MFAT should ask about the regulatory framework governing the procedure, the processing device’s status, whether a registered clinical trial is available for their condition, and what claims the provider is actually making. A clinic that answers those questions directly and in writing is a clinic worth evaluating further. A clinic that deflects the questions is a clinic worth walking away from.
Want to Learn More or Connect With a Provider?
Before taking any next step: adipose tissue banking is a preservation service for potential future use in FDA-regulated pathways, not a treatment or a guarantee of access to any specific clinical trial, therapy, or product. MFAT is an investigational procedure, not an FDA-approved treatment. No adipose-derived product is FDA-approved for general disease treatment, and banking cannot be represented to patients as one. Physicians considering partnership should independently verify applicable state licensing and informed-consent requirements, particularly in Florida, Utah, and Nevada, which have stem cell-specific statutes.
For patients, the Save My Fat overview of how banking works describes the banking process from consultation through storage, and the resource on questions to ask before banking gives patients a framework for evaluating any adipose tissue procedure, including MFAT. For patients interested in active MFAT research, the MFAT injection trial search on ClinicalTrials.gov is the primary registry.
For physicians, the Save My Fat provider program overview and the partner sign-up page are the starting points for adding banking to a practice that already offers or is evaluating MFAT.
Save My Fat provides adipose tissue banking services in partnership with L2 Bio for laboratory operations. Save My Fat does not provide MFAT injections, medical treatments, clinical trial enrollment, or Expanded Access services.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
